🟢 Kyverna Therapeutics is trading 5% up in pre-market with catalyst unconfirmed

Kyverna Therapeutics is trading at $6.51, up 5.34%, with no clear company-specific announcement dated October 9 explaining the pre-market gain.

• On October 7, Kyverna Therapeutics announced that positive clinical data would be presented at a meeting later in October; available reporting does not establish this as the cause of the gain.
• The Nasdaq Composite is up 0.87% pre-market, which may be supportive, but the move’s specific catalyst remains unconfirmed.